CNTX CONTEXT THERAPEUTICS INC

EQS-News: Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

EQS-News: Context Therapeutics
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

06.12.2022 / 12:40 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Investors USA

Proactive Investors USA


News Source: News Direct

06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Context Therapeutics
United States
ISIN: US21077P1084
EQS News ID: 1506291

 
End of News EQS News Service

1506291  06.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1506291&application_name=news&site_id=research_pool
EN
06/12/2022

Underlying

CNTXCONTEXT THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEXT THERAPEUTICS INC

 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing R...

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase 30,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context. The stock option awards were granted outside of the Context Therapeutics Inc....

October 3, 2025 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics to Participate in Upcoming Investor Conferences PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that the Company will participate in the following investor conferences: Cantor Global Healthcare Conference 2025Fireside chat: Wednesday, September 3 at 10:55 AM ET in New York, NY1x1 Meetings on September 3 H.C. Wainwright 27th Annual Global Investment ConferenceFireside ch...

August 27, 2025 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Reports Second Quarter 2025 Operating and Financi...

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 3...

August 6, 2025 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presen...

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, end...

June 2, 2025 1 EN
 PRESS RELEASE
Free
CNTX CONTEXT THERAPE...

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medica...

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment of Dr. Karen Chagin, M.D. as Chief Medical Officer (“CMO”), effective June 9, 2025. Dr. Chagin succeeds Dr. Karen Smith, M.D., Ph.D., MBA, LLM, who has been serving as interim CMO and will remain a member of the Company’s Board of Directors (“Board”). Dr. Cha...

May 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch